Liraglutide decreases methamphetamine intake in operant self-administration under short- and long-access protocols in rats
| Authors | |
|---|---|
| Year of publication | 2025 |
| Type | Appeared in Conference without Proceedings |
| MU Faculty or unit | |
| Citation | |
| Description | Substance use disorder (SUD) is a chronic relapsing disorder lacking effective pharmacological treatments. Despite decades of research, most interventions fail to prevent relapse or reduce drug intake in clinical populations, highlighting the urgent need for novel strategies. This study investigates the potential of an antidiabetic drug liraglutide – a GLP-1 receptor agonist recently approved for the treatment of obesity – in reducing methamphetamine intake and relapse-like behavior using short-access (ShA) and long-access (LgA) intravenous self-administration (IVSA) models under an FR-1 schedule. |
| Related projects: |